Carrying on from where the firm left off in 2018, the first quarter of 2019 has been a positive one for Sanofi (Euronext: SAN).
The French pharma major announced its latest quarterly financial results on Friday, and that morning the company’s share price jumped by more than 3%.
Net sales for the quarter came in at 8.39 billion euros ($9.35 billion), a 6.2% rise in reported growth compared to the first quarter of 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze